Beneficial role for supplemental vitamin D3 treatment in chronic urticaria: a randomized study
Rorie A, Goldner WS, Lyden E, Poole JA
Published in Annals of Allergy, Asthma & Immunology
Methodology
Prospective, double-blinded, single-center trial randomizing 42 chronic urticaria patients to high-dose (4,000 IU/d) or low-dose (600 IU/d) vitamin D3 for 12 weeks on top of standardized triple-drug therapy (cetirizine, ranitidine, montelukast).
Key Findings
Triple-drug therapy cut total Urticaria Symptom Severity scores 33% in week 1; a further 40% decrease occurred in the high-dose vitamin D3 group but not the low-dose group by week 12, driven by fewer affected body areas and fewer days with hives.
Conclusions
Add-on high-dose vitamin D3 may provide additional symptom relief in chronic urticaria, but the between-group difference only reached a trend (P = .052).
Limitations
Small sample, single center, background triple therapy confounds effect size, primary between-group comparison not statistically significant.
Supplements Studied
Triple-drug therapy decreased total USS scores by 33% in the first week. There was a further significant decrease (40%) in total USS scores in the high, but not low, vitamin D3 treatment group by week 12.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Academic/institutional
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.